PO.BCS01.07 · 生物信息与计算
H&E切片的深度学习为从不吸烟者的非黏液性肺腺癌提供了超越IASLC分级的预后价值
Deep learning of H&E slides adds prognostic value beyond IASLC grading in non-mucinous lung adenocarcinoma among never-smokers
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:从不吸烟者的肺癌(LCINS)最常表现为非黏液性腺癌。国际肺癌研究协会(IASLC)系统是目前组织学分级的标准,但其应用受到观察者间变异性、耗时的人工评估以及有限的可扩展性的限制。我们评估了应用于常规苏木精和伊红(H&E)切片的深度学习模型是否能够预测总生存期并改善超越常规组织学分级的预后分层。方法:我们分析了来自Sherlock-Lung研究的595张I-III期全切片图像,每张来自一名独特的患者。对于整个队列,中位随访时间为37个月(范围1-120个月);在诊断后5年内发生55例死亡,10年内发生102例死亡,总体发生190例事件。数据被分为训练集(n=409)、内部交叉验证集(n=45)和留出验证集(n=141)。一个卷积神经网络从H&E图像生成连续的患者级风险评分,在验证队列中使用Youden指数将其二分为高风险组(n=34)和低风险组(n=107)。使用时间依赖性AUC和Cox模型评估验证集中总生存期的预后区分能力。我们在单变量分析中以及基于以下Cox模型比较了由IASLC分级和深度学习风险估计的5年和10年生存概率的AUC:(1) 基线(年龄、性别、血统、肿瘤分期)+ IASLC分级;(2) 基线 + 深度学习;(3) 基线 + IASLC分级 + 深度学习。结果:深度学习在5年(0.84 [0.76-0.92] vs 0.70 [0.62-0.78];p=0.01)和10年总生存期(0.75 [0.61-0.90] vs 0.64 [0.48-0.79];p=0.59)方面产生的AUC高于IASLC分级。在多变量分析中,5年时的AUC分别为基线 + IASLC为0.79,基线 + 深度学习为0.86(vs 基线 + IASLC,p<0.01),完整模型为0.87(优于更简单的模型,p=0.04);10年时对应的AUC分别为0.82、0.86和0.87,总体上无统计学显著差异(p=0.63),这可能反映了后期事件较少。在5年随访的Cox模型中,深度学习低风险组相比高风险组具有更好的总生存期(HR 0.31,95% CI 0.13-0.76)。结论:常规H&E切片上的深度学习提供了独立于IASLC分级的LCINS预后信息。将深度学习与分级和临床因素整合可改善总生存期预测,支持AI增强的病理学用于从不吸烟者非黏液性肺腺癌的精准风险分层和个性化治疗/监测。
查看英文原文 English abstract
Background: Lung cancer in never smokers (LCINS) most often presents as non-mucinous adenocarcinoma. The International Association for the Study of Lung Cancer (IASLC) system is the current standard for histologic grading, but its use is limited by interobserver variability, time-intensive manual assessment, and limited scalability. We evaluated whether a deep learning model applied to routine hematoxylin and eosin (H&E) slides could predict overall survival and improve prognostic stratification beyond conventional histologic grading. Methods: We analyzed 595 stage I-III whole-slide images from the Sherlock-Lung study, each from a unique patient. For the full cohort, median follow-up was 37 months (range 1-120 months); 55 deaths occurred by 5 years and 102 deaths by 10 years from diagnosis, out of 190 events overall. Data were split into training (n=409), internal cross-validation (n=45), and held-out validation (n=141) sets. A convolutional neural network generated continuous patient-level risk scores from H&E images, which were dichotomized into high-risk (n=34) and low-risk (n=107) groups in the validation cohort using the Youden index. Prognostic discrimination for overall survival in the validation set was assessed using time-dependent AUCs and Cox models. We compared AUCs for 5- and 10-year survival probabilities estimated from IASLC grade and deep-learning risks in univariate analyses and based on the following Cox models: (1) baseline (age, sex, ancestry, tumor stage) + IASLC grade; (2) baseline + deep learning; (3) baseline + IASLC grade + deep learning. Results: Deep learning yielded higher AUCs than IASLC grade for 5 year (0.84 [0.76-0.92] vs 0.70 [0.62-0.78]; p=0.01) and 10 years overall survival (0.75 [0.61-0.90] vs 0.64 [0.48-0.79]; p=0.59). In multivariable analyses, at 5 years the AUCs were 0.79 for baseline + IASLC, 0.86 for baseline + deep learning (p<0.01 vs baseline + IASLC), and 0.87 for the full model (better than simpler models, p=0.04); at 10 years the corresponding AUCs were 0.82, 0.86, and 0.87, with no statistically significant differences overall (p=0.63), possibly reflecting fewer late events. In a Cox model for 5 years of follow-up the deep-learning low-risk group had improved overall survival versus the high-risk group (HR 0.31, 95% CI 0.13-0.76). Conclusions: Deep learning on routine H&E slides provides prognostic information independent of IASLC grade in LCINS. Integrating deep learning with grade and clinical factors improves overall survival prediction, supporting AI-augmented pathology for precision risk stratification and personalized treatment/surveillance in non-mucinous lung adenocarcinoma among never-smokers.
利益披露 Disclosure
M. Saha, None..
T. Tran, None..
H. Hoang, None..
P. M. Bhawsar, None..
R. Homer, None..
M. K. Baine, None.
L. M. Sholl,
Genentech Other, Research funding and consulting.
Bristol Myers Squibb Other, Research funding.
Lilly Other, Consulting.
P. Joubert, None..
C. Leduc, None..
W. D. Travis, None..
R. M. Pfeiffer, None..
J. S. Almeida, None.
S. Yang,
Medscape Other, Speaker.
OncLive Other, Speaker.
Cure Today Other, Speaker.
Medical Learning Institute Other, Speaker.
PRIME Education Other, Speaker.
AstraZeneca Other, Speaker and Consulting.
Roche Other, Speaker and Consulting.
AbbVie Other, Speaker and Consulting.
Revolution Medicines Other, Consulting.
Merus Other, Consulting.
Eli Lilly Other, Consulting.
Amgen Other, Consulting.
Sanofi Other, Consulting.
M. Landi, None.